Peter Boan

Apr 4, 2024 | onlinelibrary.wiley.com | Peter Boan |Duncan Purtill |Matthew Wright |Paul Cannell

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused devastating illness in immunocompromised patients, including recipients of haemopoietic stem cell transplant (HSCT).1 International centres report mortality rates of up to 20–40% among their HSCT patients during the pandemic.2-8 Older age (>50 years), male sex, infection within 12 months of transplantation and concurrent comorbidities (e.g. diabetes) represent risk factors for severe coronavirus-19 (COVID-19)...